220 related articles for article (PubMed ID: 34706549)
1. Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.
Olson NC; Raffield LM; Moxley AH; Miller-Fleming TW; Auer PL; Franceschini N; Ngo D; Thornton TA; Lange EM; Li Y; Nickerson DA; Zakai NA; Gerszten RE; Cox NJ; Correa A; Mohlke KL; Reiner AP
Circ Genom Precis Med; 2021 Dec; 14(6):e003421. PubMed ID: 34706549
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease.
Goodchild TT; Li Z; Lefer DJ
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519539
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
[TBL] [Abstract][Full Text] [Related]
6. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.
Hindy G; Tyrrell DJ; Vasbinder A; Wei C; Presswalla F; Wang H; Blakely P; Ozel AB; Graham S; Holton GH; Dowsett J; Fahed AC; Amadi KM; Erne GK; Tekmulla A; Ismail A; Launius C; Sotoodehnia N; Pankow JS; Thørner LW; Erikstrup C; Pedersen OB; Banasik K; Brunak S; Ullum H; Eugen-Olsen J; Ostrowski SR; ; Haas ME; Nielsen JB; Lotta LA; ; Engström G; Melander O; Orho-Melander M; Zhao L; Murthy VL; Pinsky DJ; Willer CJ; Heckbert SR; Reiser J; Goldstein DR; Desch KC; Hayek SS
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36194491
[TBL] [Abstract][Full Text] [Related]
7. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
[TBL] [Abstract][Full Text] [Related]
8. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE
Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228
[TBL] [Abstract][Full Text] [Related]
10. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
Wu W; Cui Y; Hu J; Liao R; Li S; Mo L; Xu L; Chen Y; Lian Z; Tian X; Li Z; Li R; Zhang L; Liang H; Ma J; Lin T; Feng Z; Dong W; Ke G; Ge P; Ye Z; Wang W; Zhang B; Shi W; Liang X; Liu S
Kidney Blood Press Res; 2018; 43(3):664-672. PubMed ID: 29734173
[TBL] [Abstract][Full Text] [Related]
11. Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
Dowsett J; Ferkingstad E; Rasmussen LJH; Thørner LW; Magnússon MK; Sugden K; Thorleifsson G; Frigge M; Burgdorf KS; Ostrowski SR; Sørensen E; Erikstrup C; Pedersen OB; Hansen TF; Banasik K; Brunak S; ; Tragante V; Lund SH; Stefansdottir L; Gunnarson B; Poulton R; Arseneault L; Caspi A; Moffitt TE; Gudbjartsson D; Eugen-Olsen J; Stefánsson H; Stefánsson K; Ullum H
Commun Biol; 2021 Jun; 4(1):655. PubMed ID: 34079037
[TBL] [Abstract][Full Text] [Related]
12. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
[TBL] [Abstract][Full Text] [Related]
14. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality.
Törnkvist PBS; Haupt TH; Rasmussen LJH; Ladelund S; Toft U; Pisinger C; Eugen-Olsen J
Br J Nutr; 2019 Mar; 121(6):699-708. PubMed ID: 30626457
[TBL] [Abstract][Full Text] [Related]
16. Associations of suPAR with lifestyle and cardiometabolic risk factors.
Botha S; Fourie CM; Schutte R; Kruger A; Schutte AE
Eur J Clin Invest; 2014 Jul; 44(7):619-26. PubMed ID: 24810168
[TBL] [Abstract][Full Text] [Related]
17. Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease.
Ismail A; Hayek SS
Curr Cardiol Rep; 2023 Dec; 25(12):1797-1810. PubMed ID: 37948017
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients.
Guan J; Gong S; He Q; Wang X; Shen S; Wu X; Shan J; Gong T; Yang Y; Xie H
Int Urol Nephrol; 2024 Jan; 56(1):191-198. PubMed ID: 37195572
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
[TBL] [Abstract][Full Text] [Related]
20. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
